Quarterly ResultMay 13, 2026, 09:12 AM
VERU Q1 Net Loss $(2.74)M; Cash $27.6M; Going Concern Warning
AI Summary
VERU INC. reported a net loss of $(2.74) million for the three months ended March 31, 2026, a significant improvement from $(7.90) million in the prior year. The company's cash, cash equivalents, and restricted cash increased to $27.6 million from $15.8 million at September 30, 2025, primarily due to a public offering that generated $23.4 million. Despite the improved cash position, management has concluded that substantial doubt exists regarding its ability to continue as a going concern for the next twelve months, citing insufficient capital to fund operations. The company is prioritizing the development of enobosarm, with sabizabulin advancement contingent on securing additional funding.
Key Highlights
- Net loss for Q1 2026 was $(2.74) million, an improvement from $(7.90) million in Q1 2025.
- Cash, cash equivalents, and restricted cash increased to $27.6 million as of March 31, 2026, from $15.8 million at September 30, 2025.
- Net cash provided by financing activities was $23.4 million for the six months ended March 31, 2026, from a public offering.
- Net cash used in operating activities was $(15.1) million for the six months ended March 31, 2026.
- Research and development expenses decreased to $3.15 million in Q1 2026 from $3.93 million in Q1 2025.
- General and administrative expenses decreased to $4.07 million in Q1 2026 from $5.16 million in Q1 2025.
- Company issued a going concern warning, stating current cash is insufficient for the next 12 months.
- Recognized a $351,418 gain on the sale of the FC2 business from a dispute settlement in Q1 2026.